Minu Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Minu Singh has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Prateek Bhatia
Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India
10 shared publications Prateek Bhatia
Hematology Oncology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
6 shared publicationsAmita Trehan
Hematology Oncology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
5 shared publicationsParminder Kaur
Hematology Oncology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
5 shared publications- Richa Jain
Pediatric Hematology Oncology Unit, Department of Pediatrics Postgraduate Institute of Medical Education and Research (PGIMER) Chandigarh India
4 shared publications Sreejesh Sreedharanunni
Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
4 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Springer Nature in Blood Research
- Vol. 61 (1) , 73
Linking sORFs and microproteins in hematological malignancies: current update on origin, function and clinical implications
- 11 November 2026
- Published by Springer Nature in Blood Research
- Vol. 61 (1) , 73
Open AccessLinking sORFs and microproteins in hematological malignancies: current update on origin, function and clinical implications
- Open Access
- 22 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (21) , 3447
Good Enough to Sequence: Fluorometry-Guided Salvage of Low-Volume and Compromised Paediatric DNA in Custom Amplicon Next-Generation Sequencing
Introduction: Amplicon-based next-generation sequencing (NGS) is widely used in clinical practice, yet few studies address the impact of fluorometric quality control and of low-volume or compromised paediatric samples on library quantification and sequencing metrics. We reframe this question around a practical goal: whether sub-optimal paediatric DNA can be reliably salvaged for custom-panel amplicon NGS. Materials and Methods: Data from 314 paediatric samples sequenced on 16 custom-designed amplicon panels (Ion Torrent S5) were analysed retrospectively by Qubit input quantity (Group A ≥ 10 ng/µL; Group B < 10 ng/µL) and Nanoquant A260/280 quality (Group C 1.7–1.9; Group D < 1.7 or >1.9), and compared against post-library quantification, mean depth, and ten coverage QC parameters. Method agreement (Bland–Altman, proportional-bias regression), effect sizes (Cliff’s δ), panel-adjusted mixed-effects models and ROC/logistic prediction of library failure were added. Results: Median input was 59.75 ng/µL by Nanoquant and 28.25 ng/µL by Qubit (p < 0.0001); median A260/280 was 1.86. Nanoquant overestimated DNA ~2.1-fold, but Bland–Altman analysis revealed wide, concentration-dependent limits of agreement (mean ratio 2.17×; 95% LoA 0.57–8.33×; proportional-bias p < 0.0001), indicating that no single correction factor is reliable. Group A comprised 91.7% (288/314) and Group B 8.3% (26/314); Group C 75.2% (236/314) and Group D 24.8% (78/314). Median post-library Qubit and mean depth were 1254 vs. 552 ng/mL (p < 0.0001) and 848× vs. 1352× (p = 0.025) for A vs. B, and 1254 vs. 1026 ng/mL (p = 0.049) and 745× vs. 1297× (p < 0.0001) for C vs. D. The higher depth in quantity Group B lost significance after adjusting for panel (mixed-model p = 0.083), identifying it as confounding. Input DNA predicted library failure (n = 5 per group) that was underpowered for formal equivalence testing. An empirical input threshold of ≈20 ng/µL, roughly double the manufacturer’s minimum, best protects against library failure.
- 22 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (21) , 3447
Open AccessGood Enough to Sequence: Fluorometry-Guided Salvage of Low-Volume and Compromised Paediatric DNA in Custom Amplicon Next-Generation Sequencing
Introduction: Amplicon-based next-generation sequencing (NGS) is widely used in clinical practice, yet few studies address the impact of fluorometric quality control and of low-volume or compromised paediatric samples on library quantification and sequencing metrics. We reframe this question around a practical goal: whether sub-optimal paediatric DNA can be reliably salvaged for custom-panel amplicon NGS. Materials and Methods: Data from 314 paediatric samples sequenced on 16 custom-designed amplicon panels (Ion Torrent S5) were analysed retrospectively by Qubit input quantity (Group A ≥ 10 ng/µL; Group B < 10 ng/µL) and Nanoquant A260/280 quality (Group C 1.7–1.9; Group D < 1.7 or >1.9), and compared against post-library quantification, mean depth, and ten coverage QC parameters. Method agreement (Bland–Altman, proportional-bias regression), effect sizes (Cliff’s δ), panel-adjusted mixed-effects models and ROC/logistic prediction of library failure were added. Results: Median input was 59.75 ng/µL by Nanoquant and 28.25 ng/µL by Qubit (p < 0.0001); median A260/280 was 1.86. Nanoquant overestimated DNA ~2.1-fold, but Bland–Altman analysis revealed wide, concentration-dependent limits of agreement (mean ratio 2.17×; 95% LoA 0.57–8.33×; proportional-bias p < 0.0001), indicating that no single correction factor is reliable. Group A comprised 91.7% (288/314) and Group B 8.3% (26/314); Group C 75.2% (236/314) and Group D 24.8% (78/314). Median post-library Qubit and mean depth were 1254 vs. 552 ng/mL (p < 0.0001) and 848× vs. 1352× (p = 0.025) for A vs. B, and 1254 vs. 1026 ng/mL (p = 0.049) and 745× vs. 1297× (p < 0.0001) for C vs. D. The higher depth in quantity Group B lost significance after adjusting for panel (mixed-model p = 0.083), identifying it as confounding. Input DNA predicted library failure (n = 5 per group) that was underpowered for formal equivalence testing. An empirical input threshold of ≈20 ng/µL, roughly double the manufacturer’s minimum, best protects against library failure.
- Open Access
- 11 September 2026
- Published by Springer Nature in Discover Oncology
Differential expression analysis of miRNAs and identification of potential key genes in pediatric T-cell acute lymphoblastic leukemia
- 11 September 2026
- Published by Springer Nature in Discover Oncology
Open AccessDifferential expression analysis of miRNAs and identification of potential key genes in pediatric T-cell acute lymphoblastic leukemia
- 23 June 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
TP53 isoform dysregulation in pediatric B-ALL: identifying markers of favorable prognosis and relapse-associated dynamic
TP53 isoforms produced by alternate splicing and promoter usage are shown to play a role in pathogenesis, chemoresistance and relapse in various cancers. Our present study focused on analyzing the expression of different TP53 isoforms in pediatric B cell acute lymphoblastic leukemia (B-ALL). We performed the transcriptomic analysis of TP53 isoforms expression in publicly available datasets followed by RT-qPCR in our cohort of pediatric B-ALL and correlated with various clinical and hematological parameters. Transcriptomic data on B-ALL available online showed overexpression of p53α in B-ALL cases at diagnosis while Δ40p53, p53β and Δ133p53 were downregulated in cases at relapse. In our cohort data (n = 99) at diagnosis, we found the upregulation of the long isoform p53α in 65.65% of patients and the short isoforms Δ133p53 in 61.61% patients and Δ40p53 in 27.27% of the patients, respectively. The over-expression of p53γ and p53β was noted in 19.19% and 14.14% of patients, respectively. To check if TP53 gene mutation contributed to this dysregulated isoform expression, we analysed the whole exome data of our B-ALL patients (n = 88). As expected only 3.7% of patients showed mutation in TP53 gene. Further, we analysed the correlation with various clinical parameters and found positive association of Δ133p53 with ETV6::RUNX1 gene fusion (p = 0.032) which is a known marker of good prognosis in B-ALL. To further validate this observation, we enrolled B-ALL relapse cases (n = 46) where samples at diagnosis were also available (n = 12). Analysis of TP53 isoforms expression in relapse B-ALL patients showed significant reduction in the expression of short isoforms of TP53 i.e. Δ133p53 (p = 0.0036) and Δ40p53 (p = 0.032). Our data show that TP53 isoforms are dysregulated in B-ALL at diagnosis as well as at relapse. Short TP53 isoforms, particularly Δ133p53 is associated with better prognosis suggesting its potential role in refining risk stratification of B-ALL.
- 23 June 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
TP53 isoform dysregulation in pediatric B-ALL: identifying markers of favorable prognosis and relapse-associated dynamic
TP53 isoforms produced by alternate splicing and promoter usage are shown to play a role in pathogenesis, chemoresistance and relapse in various cancers. Our present study focused on analyzing the expression of different TP53 isoforms in pediatric B cell acute lymphoblastic leukemia (B-ALL). We performed the transcriptomic analysis of TP53 isoforms expression in publicly available datasets followed by RT-qPCR in our cohort of pediatric B-ALL and correlated with various clinical and hematological parameters. Transcriptomic data on B-ALL available online showed overexpression of p53α in B-ALL cases at diagnosis while Δ40p53, p53β and Δ133p53 were downregulated in cases at relapse. In our cohort data (n = 99) at diagnosis, we found the upregulation of the long isoform p53α in 65.65% of patients and the short isoforms Δ133p53 in 61.61% patients and Δ40p53 in 27.27% of the patients, respectively. The over-expression of p53γ and p53β was noted in 19.19% and 14.14% of patients, respectively. To check if TP53 gene mutation contributed to this dysregulated isoform expression, we analysed the whole exome data of our B-ALL patients (n = 88). As expected only 3.7% of patients showed mutation in TP53 gene. Further, we analysed the correlation with various clinical parameters and found positive association of Δ133p53 with ETV6::RUNX1 gene fusion (p = 0.032) which is a known marker of good prognosis in B-ALL. To further validate this observation, we enrolled B-ALL relapse cases (n = 46) where samples at diagnosis were also available (n = 12). Analysis of TP53 isoforms expression in relapse B-ALL patients showed significant reduction in the expression of short isoforms of TP53 i.e. Δ133p53 (p = 0.0036) and Δ40p53 (p = 0.032). Our data show that TP53 isoforms are dysregulated in B-ALL at diagnosis as well as at relapse. Short TP53 isoforms, particularly Δ133p53 is associated with better prognosis suggesting its potential role in refining risk stratification of B-ALL.
- Open Access
- 16 May 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1) , 21
VEXAS syndrome: a comprehensive clinicopathologic and genetic analysis of a predominantly Indian cohort
Background: VEXAS syndrome is a recently recognized, acquired monogenic adult onset hemato-inflammatory syndrome characterized by somatic mutations within the UBA1 gene. The acronym VEXAS stands for vacuoles, E1 enzyme, X-linked inheritance, autoinflammatory tendencies, and somatic mutations. It presents as a severe progressive disease displaying varied characteristics that bridge hematologic and rheumatologic domains. Herein, we describe a series with a detailed evaluation of 11 cases of VEXAS syndrome. Materials and methods: A comprehensive retrospective analysis of patients diagnosed with VEXAS syndrome over the last 5 years (2020–2025) was conducted. Data on clinical presentation, histopathological findings, genetic characteristics, and outcomes were recorded for systematic characterization. Results: A total of 11 cases of VEXAS syndrome were identified. All the patients were males with an age range from 42 to 77 years. Prominent clinical characteristics included history of fever (11), arthritis/arthralgia (10), inflammatory skin lesions (7), vasculitis (6), ocular inflammatory conditions (6), relapsing polychondritis (6), unprovoked venous thrombosis (5), and auricular chondritis (4). Persistent unexplained cytopenia was present in all the patients, manifesting as anemia (10, 8 of which were macrocytic), thrombocytopenia (4), and neutropenia (2). Bone marrow examination was performed in nine cases, five showed morphologic dysplasia. Furthermore, all nine cases characteristically showed cytoplasmic vacuolations in hematopoietic precursors. UBA1 somatic mutations included p.Met41Thr (c.122 T>C Exon 3) (55%), p.Met41Val (c.121 A>G Exon 3) (27%), p.Met41Leu (c.121 A>C Exon 3) (9%), and a variant in the acceptor splice site of Exon 3 (c.118 G>C) (9%). p.Met41Val is associated with inferior overall survival (OS). Conclusion: This study characterizes the clinical, morphologic, and laboratory features of VEXAS syndrome and presents the first comprehensive patient cohort from India. With a complex and heterogeneous clinical profile, awareness of the disease is particularly essential among hematologists, rheumatologists, and dermatologists for accurate diagnosis and management.
- 16 May 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1) , 21
Open AccessVEXAS syndrome: a comprehensive clinicopathologic and genetic analysis of a predominantly Indian cohort
Background: VEXAS syndrome is a recently recognized, acquired monogenic adult onset hemato-inflammatory syndrome characterized by somatic mutations within the UBA1 gene. The acronym VEXAS stands for vacuoles, E1 enzyme, X-linked inheritance, autoinflammatory tendencies, and somatic mutations. It presents as a severe progressive disease displaying varied characteristics that bridge hematologic and rheumatologic domains. Herein, we describe a series with a detailed evaluation of 11 cases of VEXAS syndrome. Materials and methods: A comprehensive retrospective analysis of patients diagnosed with VEXAS syndrome over the last 5 years (2020–2025) was conducted. Data on clinical presentation, histopathological findings, genetic characteristics, and outcomes were recorded for systematic characterization. Results: A total of 11 cases of VEXAS syndrome were identified. All the patients were males with an age range from 42 to 77 years. Prominent clinical characteristics included history of fever (11), arthritis/arthralgia (10), inflammatory skin lesions (7), vasculitis (6), ocular inflammatory conditions (6), relapsing polychondritis (6), unprovoked venous thrombosis (5), and auricular chondritis (4). Persistent unexplained cytopenia was present in all the patients, manifesting as anemia (10, 8 of which were macrocytic), thrombocytopenia (4), and neutropenia (2). Bone marrow examination was performed in nine cases, five showed morphologic dysplasia. Furthermore, all nine cases characteristically showed cytoplasmic vacuolations in hematopoietic precursors. UBA1 somatic mutations included p.Met41Thr (c.122 T>C Exon 3) (55%), p.Met41Val (c.121 A>G Exon 3) (27%), p.Met41Leu (c.121 A>C Exon 3) (9%), and a variant in the acceptor splice site of Exon 3 (c.118 G>C) (9%). p.Met41Val is associated with inferior overall survival (OS). Conclusion: This study characterizes the clinical, morphologic, and laboratory features of VEXAS syndrome and presents the first comprehensive patient cohort from India. With a complex and heterogeneous clinical profile, awareness of the disease is particularly essential among hematologists, rheumatologists, and dermatologists for accurate diagnosis and management.
- Open Access
- 27 August 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (9) , 1238
Altered Expression of m6A-Associated Genes Is Linked with Poor Prognosis in Pediatric Acute Myeloid Leukemia Patients
The dysregulation of m6A-related genes recognized as ‘writers’, ‘readers’, and ‘erasers’ is reported to be involved in the initiation, progression, and drug resistance of acute myeloid leukemia (AML). In the present study, we investigated the expression levels of various readers, writers, and erasers in pediatric AML patients. Additionally, we categorized the patients according to the molecular subtyping of common mutations and recurrent fusions and correlated the expression of m6A-associated genes with different molecular subtypes and evaluated their prognostic and clinical implications. A total of fifty-seven patients with pediatric de novo AML were enrolled in the study. The study cohort consisted of 41 males and 16 females with a median age of 7 years (range 1 to 12 years). A high expression of m6A RNA modification complex genes was noted in AML patients. Among the writers, METTL3 and METTL14 were found to be upregulated in 19 and 17 patients, the readers YTHDF1 and YTHDF2 showed higher expression in 6 and 10 patients, while a high expression of erasers FTO and ALKBH5 was found in 28 patients and 1 patient, respectively. Further, the expression of m6A regulators showed a significant association with genetic alterations including FLT3-ITD, RBM15::MKL fusions and NPM1 mutations. Additionally, while evaluating the prognostic implications, both the readers YTHDF1 and YTHDF2 showed a significant correlation with TLC at diagnosis (p < 0.05). Further, Kaplan–Meier estimation showed a poor event-free survival in cases with the overexpression of YTHDF1 (log-rank p = 0.028). Additionally, we noted a strong correlation between YTHDF1 overexpression and treatment-related mortality (log-rank p < 0.001), and a nearly significant correlation with YTHDF2 expression in such patients (log-rank p = 0.053) at a median follow-up of 8 months. Thus, our data suggest that m6A genes, especially readers YTHDF1 and YTHDF2, are involved in the disease prognosis of AML and probably function in an integrated manner with other m6A-modifying genes to subsequently play a role in AML pathogenesis.
- 27 August 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (9) , 1238
Open AccessAltered Expression of m6A-Associated Genes Is Linked with Poor Prognosis in Pediatric Acute Myeloid Leukemia Patients
The dysregulation of m6A-related genes recognized as ‘writers’, ‘readers’, and ‘erasers’ is reported to be involved in the initiation, progression, and drug resistance of acute myeloid leukemia (AML). In the present study, we investigated the expression levels of various readers, writers, and erasers in pediatric AML patients. Additionally, we categorized the patients according to the molecular subtyping of common mutations and recurrent fusions and correlated the expression of m6A-associated genes with different molecular subtypes and evaluated their prognostic and clinical implications. A total of fifty-seven patients with pediatric de novo AML were enrolled in the study. The study cohort consisted of 41 males and 16 females with a median age of 7 years (range 1 to 12 years). A high expression of m6A RNA modification complex genes was noted in AML patients. Among the writers, METTL3 and METTL14 were found to be upregulated in 19 and 17 patients, the readers YTHDF1 and YTHDF2 showed higher expression in 6 and 10 patients, while a high expression of erasers FTO and ALKBH5 was found in 28 patients and 1 patient, respectively. Further, the expression of m6A regulators showed a significant association with genetic alterations including FLT3-ITD, RBM15::MKL fusions and NPM1 mutations. Additionally, while evaluating the prognostic implications, both the readers YTHDF1 and YTHDF2 showed a significant correlation with TLC at diagnosis (p < 0.05). Further, Kaplan–Meier estimation showed a poor event-free survival in cases with the overexpression of YTHDF1 (log-rank p = 0.028). Additionally, we noted a strong correlation between YTHDF1 overexpression and treatment-related mortality (log-rank p < 0.001), and a nearly significant correlation with YTHDF2 expression in such patients (log-rank p = 0.053) at a median follow-up of 8 months. Thus, our data suggest that m6A genes, especially readers YTHDF1 and YTHDF2, are involved in the disease prognosis of AML and probably function in an integrated manner with other m6A-modifying genes to subsequently play a role in AML pathogenesis.
- 11 February 2025
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 18 (3) , 175-183
Effectiveness and safety of thiopurines in inflammatory bowel disease patients with NUDT15 polymorphism: a real-world retrospective study
Thiopurine S-methyltransferase (TPMT) and Nudix hydrolase (NUDT15) polymorphisms predispose to thiopurine-related leukopenia. Retrospective evaluation of inflammatory bowel disease (IBD) patients harboring NUDT15 polymorphisms and exposed to thiopurines. We report the frequency of NUDT15 polymorphism, frequency of leukopenia, the tolerated dose of azathioprine, and the clinical efficacy of thiopurines. Of 1440 patients, 118 (8.2%) had NUDT15 polymorphism. Among 51 with complete details, 46 were heterozygous (90.2%), and 5 homozygous (9.2%) for NUDT15. Twenty (43.5%) heterozygous and all homozygous patients developed leukopenia. Leukopenia was significantly more in NUDT15 heterozygous group compared to controls (43.45% vs 7.8%, Odds ratio: 9, 95% CI 3.57-22.9). The maximum tolerated dose of azathioprine was lower in NUDT15 heterozygous group (1.1 ± 0.4 mg per kg vs 1.7 ± 0.7 mg per kg, p = 0.002). The mean time to leukopenia was earlier in the heterozygous group vs controls (19 ± 56 weeks vs 70 ± 53 weeks, p-value 0.002). Seven (35%) of 20 heterozygous patients who developed leukopenia, could be maintained at a lower dose of thiopurine. Twenty-five maintained clinical remission while on thiopurines. Thiopurines should be avoided in NUDT15 homozygous but can be used cautiously at lower dosages with frequent monitoring among heterozygous patients.
- 11 February 2025
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 18 (3) , 175-183
Effectiveness and safety of thiopurines in inflammatory bowel disease patients with NUDT15 polymorphism: a real-world retrospective study
Thiopurine S-methyltransferase (TPMT) and Nudix hydrolase (NUDT15) polymorphisms predispose to thiopurine-related leukopenia. Retrospective evaluation of inflammatory bowel disease (IBD) patients harboring NUDT15 polymorphisms and exposed to thiopurines. We report the frequency of NUDT15 polymorphism, frequency of leukopenia, the tolerated dose of azathioprine, and the clinical efficacy of thiopurines. Of 1440 patients, 118 (8.2%) had NUDT15 polymorphism. Among 51 with complete details, 46 were heterozygous (90.2%), and 5 homozygous (9.2%) for NUDT15. Twenty (43.5%) heterozygous and all homozygous patients developed leukopenia. Leukopenia was significantly more in NUDT15 heterozygous group compared to controls (43.45% vs 7.8%, Odds ratio: 9, 95% CI 3.57-22.9). The maximum tolerated dose of azathioprine was lower in NUDT15 heterozygous group (1.1 ± 0.4 mg per kg vs 1.7 ± 0.7 mg per kg, p = 0.002). The mean time to leukopenia was earlier in the heterozygous group vs controls (19 ± 56 weeks vs 70 ± 53 weeks, p-value 0.002). Seven (35%) of 20 heterozygous patients who developed leukopenia, could be maintained at a lower dose of thiopurine. Twenty-five maintained clinical remission while on thiopurines. Thiopurines should be avoided in NUDT15 homozygous but can be used cautiously at lower dosages with frequent monitoring among heterozygous patients.
- Open Access
- 29 November 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-15
Recent advances on biogenesis, functions and therapeutic potential of long noncoding RNAs in T cell acute lymphoblastic leukemia
T-cell Acute Lymphoblastic Leukemia (T-ALL) is a highly aggressive form of ALL with at least 25% relapse rates. The high relapse rates are often linked to poor prognoses. More detailed studies for novel therapeutic targets for the treatment of T-ALL are required as the genetic and transcriptomic data currently available on T-ALL pathophysiology is insufficient. Long non-coding RNAs are emerging as important players in the regulation of tumour proliferation and metastasis. Studies on various cancers have revealed their potential as biomarkers and therapeutic targets in treatment. This review describes the characterization, biosynthesis, and role of long non-coding RNA in T-ALL and highlights their potential as next generation molecule in development of promising diagnostic, prognostic and/or therapeutic markers.
- 29 November 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-15
Open AccessRecent advances on biogenesis, functions and therapeutic potential of long noncoding RNAs in T cell acute lymphoblastic leukemia
T-cell Acute Lymphoblastic Leukemia (T-ALL) is a highly aggressive form of ALL with at least 25% relapse rates. The high relapse rates are often linked to poor prognoses. More detailed studies for novel therapeutic targets for the treatment of T-ALL are required as the genetic and transcriptomic data currently available on T-ALL pathophysiology is insufficient. Long non-coding RNAs are emerging as important players in the regulation of tumour proliferation and metastasis. Studies on various cancers have revealed their potential as biomarkers and therapeutic targets in treatment. This review describes the characterization, biosynthesis, and role of long non-coding RNA in T-ALL and highlights their potential as next generation molecule in development of promising diagnostic, prognostic and/or therapeutic markers.
- Open Access
- 12 November 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1445794
Current insights on m6A RNA modification in acute leukemia: therapeutic targets and future prospects
RNA modification is the critical mechanism for regulating post-transcriptional processes. There are more than 150 RNA modifications reported so far, among which N6-Methyladenosine is the most prevalent one. M6A RNA modification complex consists of ‘writers’, ‘readers’ and ‘erasers’ which together in a group catalyze, recognize and regulate the methylation process of RNA and thereby regulate the stability and translation of mRNA. The discovery of erasers also known as demethylases, revolutionized the research on RNA modifications as it revealed that this modification is reversible. Since then, various studies have focused on discovering the role of m6A modification in various diseases especially cancers. Aberrant expression of these ‘readers’, ‘writers’, and ‘erasers’ is found to be altered in various cancers resulting in disturbance of cellular homeostasis. Acute leukemias are the most common cancer found in pediatric patients and account for 20% of adult cases. Dysregulation of the RNA modifying complex have been reported in development and progression of hematopoietic malignancies. Further, targeting m6A modification is the new approach for cancer immunotherapy and is being explored extensively. This review provides detailed information about current information on the role of m6A RNA modification in acute leukemia and their therapeutic potential.
- 12 November 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1445794
Open AccessCurrent insights on m6A RNA modification in acute leukemia: therapeutic targets and future prospects
RNA modification is the critical mechanism for regulating post-transcriptional processes. There are more than 150 RNA modifications reported so far, among which N6-Methyladenosine is the most prevalent one. M6A RNA modification complex consists of ‘writers’, ‘readers’ and ‘erasers’ which together in a group catalyze, recognize and regulate the methylation process of RNA and thereby regulate the stability and translation of mRNA. The discovery of erasers also known as demethylases, revolutionized the research on RNA modifications as it revealed that this modification is reversible. Since then, various studies have focused on discovering the role of m6A modification in various diseases especially cancers. Aberrant expression of these ‘readers’, ‘writers’, and ‘erasers’ is found to be altered in various cancers resulting in disturbance of cellular homeostasis. Acute leukemias are the most common cancer found in pediatric patients and account for 20% of adult cases. Dysregulation of the RNA modifying complex have been reported in development and progression of hematopoietic malignancies. Further, targeting m6A modification is the new approach for cancer immunotherapy and is being explored extensively. This review provides detailed information about current information on the role of m6A RNA modification in acute leukemia and their therapeutic potential.
- 12 October 2024
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 41 (8) , 620-632
Assessment of cancer predisposition syndromes in children with leukemia and solid tumors: germline-genomic profiling and clinical features in a series of cases
Cancer predisposition syndromes (CPS) are a group of genetic disorders that increase the risk of various cancers. Identifying CPS has a significant impact on the treatment plan, screening and follow-up strategy, and genetic counseling of the family. However, in children, it goes underdiagnosed in most clinical setups, especially in low- and middle-income (LMIC) countries. In the present study, we screened 60 pediatric oncology patients for a possible CPS based on pre-defined selection criteria. Six patients met the criteria, three of whom had hematological malignancy, while the remaining three had sarcoma. Whole exome sequencing was performed in the selected patients to confirm the diagnosis. Germline mutation in CPS-related genes was discovered in five of six cases, including novel mutations discovered in two. An adverse outcome was observed in all five patients with underlying cancer predisposition syndrome, with three having relapsed and two having progressive disease. Our study reflects a prevalence of 10% underlying CPS in a limited cohort of patient based on the phenotype-genotype approach in our cohort. Using pre-defined clinical selection criteria, screening can be directed to a high-risk patient cohort with high-pick up rate for CPS. The selection criteria could be utilized in any LMIC-based clinical setup for pediatric cancer patients who may benefit from modification of treatment as well as genetic counseling.
- 12 October 2024
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 41 (8) , 620-632
Assessment of cancer predisposition syndromes in children with leukemia and solid tumors: germline-genomic profiling and clinical features in a series of cases
Cancer predisposition syndromes (CPS) are a group of genetic disorders that increase the risk of various cancers. Identifying CPS has a significant impact on the treatment plan, screening and follow-up strategy, and genetic counseling of the family. However, in children, it goes underdiagnosed in most clinical setups, especially in low- and middle-income (LMIC) countries. In the present study, we screened 60 pediatric oncology patients for a possible CPS based on pre-defined selection criteria. Six patients met the criteria, three of whom had hematological malignancy, while the remaining three had sarcoma. Whole exome sequencing was performed in the selected patients to confirm the diagnosis. Germline mutation in CPS-related genes was discovered in five of six cases, including novel mutations discovered in two. An adverse outcome was observed in all five patients with underlying cancer predisposition syndrome, with three having relapsed and two having progressive disease. Our study reflects a prevalence of 10% underlying CPS in a limited cohort of patient based on the phenotype-genotype approach in our cohort. Using pre-defined clinical selection criteria, screening can be directed to a high-risk patient cohort with high-pick up rate for CPS. The selection criteria could be utilized in any LMIC-based clinical setup for pediatric cancer patients who may benefit from modification of treatment as well as genetic counseling.